NCT05221320: An ongoing trial by BioMed Valley Discoveries, Inc
This trial is ongoing. It must report results 1 month, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05221320 |
|---|---|
| Title | A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies Harboring Mitogen-activated Protein Kinase (MAPK) Pathway Mutations (BVD-523-HCQ) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 26, 2022 |
| Completion date | May 8, 2024 |
| Required reporting date | May 8, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |